Ipsilateral nodal recurrence after axillary dissection for breast cancer

被引:5
作者
Walsh, Nathaniel [2 ]
Kiluk, John V. [1 ]
Sun, Weihong [1 ]
Khakpour, Nazanin [1 ]
Laronga, Christine [1 ]
Lee, Marie Catherine [1 ]
机构
[1] H Lee Moffitt Canc Ctr & Res Inst, Comprehens Breast Program, Tampa, FL 33612 USA
[2] Univ S Florida, Coll Med, Tampa, FL USA
关键词
Breast cancer; Axillary node dissection; Regional nodal recurrence; SURGICAL ADJUVANT BREAST; NEOADJUVANT CHEMOTHERAPY; LOCOREGIONAL RECURRENCES; CONSERVING THERAPY; TUMOR RECURRENCE; BIOPSY; PROGNOSIS;
D O I
10.1016/j.jss.2012.02.020
中图分类号
R61 [外科手术学];
学科分类号
摘要
Introduction: Level I/II axillary lymph node dissection (ALND) is the standard operation for patients with node-positive breast cancer. The objective of this study was to assess the incidence of regional nodal recurrence (RNR) after ALND performed for definitive operative treatment for primary breast cancer. Materials and methods: A retrospective, Institutional Review Board-approved query of our single-institution National Comprehensive Cancer Network database was performed for patients undergoing ALND who developed subsequent RNR. All patients were treated from 1999 to 2009. A detailed chart review was performed and clinical, pathologic, treatment, and outcome data were collected. Results: A total of 1614 patients had an ALND for initial staging; 14/1614 (0.9%) patients had RNR. Two other patients had contralateral breast/axillary recurrences and were excluded. The mean age at diagnosis for the sample group was 52.7 y (range 34-77); mean follow-up time was 47.1 mo (range 12.6-114.6). The median number of nodes for ALND was 16 (range 8-27). The median number of positive nodes was 2.5 (range 0-7). Nine (64.3%) cases were estrogen receptor/progesterone receptor negative. Twelve (85.7%) patients had axillary recurrences, and six of 12 (50.0%) had concurrent chest wall lesions. Twelve patients (85.7%) had distant metastases; nine of 12 (75.0%) died; two were lost to follow-up. Mean time from RNR to distant recurrence was 6.0 mo (range 0-29.3 mo). Conclusions: RNR after ALND is rare but a harbinger of poor outcome. This is apparent regardless of treatment used for initial disease or recurrence. Specifically, RNR after primary ALND is related to increased risk of mortality and distant metastatic disease. (C) 2012 Elsevier Inc. All rights reserved.
引用
收藏
页码:81 / 86
页数:6
相关论文
共 24 条
[1]   Prognosis After Ipsilateral Breast Tumor Recurrence and Locoregional Recurrences in Patients Treated by Breast-Conserving Therapy in Five National Surgical Adjuvant Breast and Bowel Project Protocols of Node-Negative Breast Cancer [J].
Anderson, Stewart J. ;
Wapnir, Irene ;
Dignam, James J. ;
Fisher, Bernard ;
Mamounas, Eleftherios P. ;
Jeong, Jong-Hyeon ;
Geyer, Charles E., Jr. ;
Wickerham, D. Lawrence ;
Costantino, Joseph P. ;
Wolmark, Norman .
JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15) :2466-2473
[2]  
Belaid A, 2010, Cancer Radiother, V14 Suppl 1, pS136, DOI 10.1016/S1278-3218(10)70017-2
[3]   Neoadjuvant chemotherapy in invasive breast cancer results in a lower axillary lymph node count [J].
Belanger, Julie ;
Soucy, Genevieve ;
Sideris, Lucas ;
Leblanc, Guy ;
Drolet, Pierre ;
Mitchell, Andrew ;
Leclerc, Yves-Eugene ;
Beaudet, Julie ;
Dufresne, Michel-Pierre ;
Dube, Pierre .
JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS, 2008, 206 (04) :704-708
[4]   Breast-conserving therapy after neoadjuvant chemotherapy: Long-term results [J].
Beriwal, S ;
Schwartz, GF ;
Komarnicky, L ;
Garcia-Young, JA .
BREAST JOURNAL, 2006, 12 (02) :159-164
[5]   Predictors of local-regional recurrence after neoadjuvant chemotherapy and mastectomy without radiation [J].
Buchholz, TA ;
Tucker, SL ;
Masullo, L ;
Kuerer, HM ;
Erwin, J ;
Salas, J ;
Frye, D ;
Strom, EA ;
McNeese, MD ;
Perkins, G ;
Katz, A ;
Singletary, SE ;
Hunt, KK ;
Buzdar, AU ;
Hortobagyi, GN .
JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (01) :17-23
[6]   Breast conservation after neoadjuvant chemotherapy: The M.D. Anderson Cancer Center experience [J].
Chen, AM ;
Meric-Bernstam, F ;
Hunt, KK ;
Thames, HD ;
Oswald, MJ ;
Outlaw, ED ;
Strom, EA ;
McNeese, MD ;
Kuerer, HM ;
Ross, MI ;
Singletary, SE ;
Ames, FC ;
Feig, BW ;
Sahin, AA ;
Perkins, GH ;
Schechter, NR ;
Hortobagyi, GN ;
Buchholz, TA .
JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (12) :2303-2312
[7]   Clinical axillary recurrence in breast cancer patients after a negative sentinel node biopsy. [J].
Chung, MA ;
Steinhoff, MA ;
Cady, B .
AMERICAN JOURNAL OF SURGERY, 2002, 184 (04) :310-314
[8]   Guidelines for sentinel node biopsy and lymphatic mapping of patients with breast cancer [J].
Cox, CE ;
Pendas, S ;
Cox, JM ;
Joseph, E ;
Shons, AR ;
Yeatman, T ;
Ku, NN ;
Lyman, GH ;
Berman, C ;
Haddad, F ;
Reintgen, DS .
ANNALS OF SURGERY, 1998, 227 (05) :645-653
[9]   Completion of Axillary Dissection for a Positive Sentinel Node: Necessary or Not? [J].
Erb, Kathleen M. ;
Julian, Thomas B. .
CURRENT ONCOLOGY REPORTS, 2009, 11 (01) :15-20
[10]   Effect of preoperative chemotherapy on the outcome of women with operable breast cancer [J].
Fisher, B ;
Bryant, J ;
Wolmark, N ;
Mamounas, E ;
Brown, A ;
Fisher, ER ;
Wickerham, DL ;
Begovic, M ;
DeCillis, A ;
Robidoux, A ;
Margolese, RG ;
Cruz, AB ;
Hoehn, JL ;
Lees, AW ;
Dimitrov, NV ;
Bear, HD .
JOURNAL OF CLINICAL ONCOLOGY, 1998, 16 (08) :2672-2685